Nilotinib Zentiva (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling pathways that promote uncontrolled proliferation of leukemic cells, thereby reducing disease activity and supporting remission in patients with BCR‑ABL‑positive leukemia.

The dose of Nilotinib Zentiva is individualized by the prescribing physician based on the patient’s disease phase, prior therapy, liver function, and potential drug interactions. Clinicians follow approved labeling and adjust the regimen according to clinical response and tolerability.

Nilotinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is also contraindicated because the drug can be excreted in milk.

To order Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and selectivity compared with first‑generation agents such as imatinib. Clinical studies have shown faster and deeper molecular responses in many patients, although the safety profile includes a higher incidence of cardiovascular and metabolic effects that require monitoring.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and extreme heat. Do not store in the bathroom or near a kitchen sink, and keep out of reach of children.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal or on an empty stomach as directed by the prescriber. The tablets should be swallowed whole with water; they must not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include cardiovascular events such as arterial occlusion, QT interval prolongation that can lead to life‑threatening arrhythmias, severe pancreatitis, hepatic failure, and pulmonary arterial hypertension. Patients should be monitored regularly for cardiac function, electrolytes, liver enzymes, and signs of vascular complications.

Nilotinib should not be used by patients with known hypersensitivity to the drug or any of its components, those with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of QT prolongation. It is also contraindicated during pregnancy and breastfeeding, and should be avoided in patients taking strong CYP3A4 inhibitors without dose adjustment.